U.S. and China: Two Systems, One Future for Nuclear Medicine?—Bridging Regulatory Gaps with Insights from 2025 FDA Breakthroughs in RPT
肖治, 国投创新投资管理有限公司副总经理
Darren XIAO, Deputy General Manager, SDIC Fund
10:45 - 11:10
主题报告5
Keynote Speech 5
新型金属螯合剂在创新核药研发中的关键作用
Critical Role of Novel Chelators in Radiopharmaceutical Development
许小鸥, 昆翎全球董事长兼首席执行官
Kevin XU, Global Chairman & CEO, ClinChoice
11:10 - 12:00
第二阶段：圆桌讨论
Session II: Panel
主持人 Moderator
杨彬, 和记黄埔医药临床开发高级副总裁、全球临床运营负责人
YANG Bin, SVP, global clinical Operation head of Hutch-med Ltd.
11:10 - 12:00
圆桌讨论
Panel
核药精准治疗的创新突破与挑战
Innovative Breakthroughs and Challenges in Precision Nuclear Medicine Therapy
讨论嘉宾： Panelist:
曹飞, 应世生物科技（南京）有限公司联合创始人、总裁兼首席财务官
Francis CAO, Co-Founder, President and CFO of InxMed (Nanjing) Co., Ltd.
吕萌, 北京大学血液病学系副主任，北京大学人民医院临床试验机构副主任、研究病房执行主任
LV Meng, Deputy Director of the Department of Hematology, Peking University; Deputy Director of the Clinical Trial Institution and Executive Director of the Research Ward, Peking University People's Hospital
王竟菁, 中国药促会器械专委会秘书长，全球健康产业创新中心执行主任
WANG Jingjing, Secretary-General of Innovative Medical Devices Specialty Committee of PhIRDA,
Executive Director, Global Health Industry Innovation Center
刘向荣, 天坛医院神经系统疾病国家临床研究中心研究员
LIU Xiangrong, Researcher, National Clinical Research Center for Neurological Diseases, Tiantan Hospital
会议咨询